Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database [PDF]
Frontiers in Pharmacology, 2023 Introduction: Drug-induced QT prolongation and (or) Torsade de Pointes (TdP) is a well-known serious adverse reaction (ADR) for some drugs, but the widely recognized comprehensive landscape of culprit-drug of QT prolongation and TdP is currently lacking ...
Dongxuan Li +10 more
doaj +3 more sources
Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study [PDF]
Frontiers in Pharmacology, 2023 Objective: Cholinesterase inhibitor (ChEIs) is the first-line drug for Alzheimer’s disease (AD). Understanding torsade de pointes (TdP)/QT prolongation with different ChEIs is essential for its safe and rational administration.
Ni Zhang +8 more
doaj +2 more sources
QT prolongation in the STREAM Stage 1 Trial. [PDF]
Int J Tuberc Lung Dis, 2022 SUMMARY BACKGROUND : STREAM (Standardized Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB) Stage 1 demonstrated non-inferior efficacy of a shortened regimen (the Short regimen) for rifampicinresistant TB (RR-TB) compared to the ...
Hughes G +6 more
europepmc +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017 BackgroundThe cardiovascular complications of cancer therapeutics are the focus of the burgeoning field of cardio‐oncology. A common challenge in this field is the impact of cancer drugs on cardiac repolarization (ie, QT prolongation) and the potential ...
Andreu Porta‐Sánchez +6 more
doaj +2 more sources
Assessing the Risk of QT Prolongation in a Psychiatric Inpatient Cohort: A Retrospective Cross-Sectional Study [PDF]
PharmaceuticalsBackground: QT prolongation is a potential serious adverse drug reaction, and assessing the risk of QT-prolonging drugs is routinely included in psychotropic medication reviews. However, the actual clinical benefits of such assessments are unknown.
Johan Frederik Mebus Meyer Christensen +5 more
doaj +2 more sources
Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment [PDF]
Scientific Reports, 2023 Drug-induced QT prolongation is attributed to several mechanisms, including hERG channel blockage. However, the risks, mechanisms, and the effects of rosuvastatin-induced QT prolongation remain unclear.
Yeryung Koo +7 more
doaj +2 more sources
Detecting QT prolongation from a single-lead ECG with deep learning. [PDF]
PLOS Digital HealthFor a number of antiarrhythmics, drug loading requires a 3-day hospitalization with continuous monitoring for QT-prolongation. Automated QT monitoring with wearable ECG monitors would enable out-of-hospital care.
Ridwan Alam +2 more
doaj +2 more sources
Ondansetron-induced QT prolongation among various age groups: a systematic review and meta-analysis [PDF]
The Egyptian Heart Journal, 2023 Background Ondansetron is a selective 5-hydroxytryptamine type 3 serotonin-receptor antagonist with antiemetic properties used inadvertently in the emergency department for controlling nausea.
Kamaldeep Singh +16 more
doaj +2 more sources
Assessing the risk of QT prolongation in primary care [PDF]
Ann Fam Med, 2023 Vishal Bhella, Divya Garg
europepmc +3 more sources
Development of a Risk Score for QT Prolongation in the Intensive Care Unit Using Time-Series Electrocardiogram Data and Electronic Medical Records [PDF]
Healthcare Informatics Research, 2021 Objectives Drug-induced QT prolongation can lead to life-threatening arrhythmia. In the intensive care unit (ICU), various drugs are administered concurrently, which can increase the risk of QT prolongation.
Tae Young Kim +4 more
doaj +1 more source